Pharma & Biotech

As the market anticipates its upcoming financial release, Iqvia has announced a significant expansion of its strategic footprint through a...

Protalix Biotherapeutics is entering a period defined by significant upcoming regulatory and clinical milestones. Following a strategic update in early...

Eli Lilly & Co. is executing a rapid and ambitious strategy to broaden its therapeutic reach. In a concentrated burst...

The telemedicine provider Hims & Hers is navigating a complex competitive landscape. Amid recent pressure on its share price, the...

Biotechnology firm VolitionRX Ltd. enters a critical period marked by two significant corporate developments: the release of fresh clinical study...

Hercules Capital, a leading specialty finance company, has significantly increased its exposure to the life sciences sector through two major...

While Viking Therapeutics shares continue to navigate a challenging correction, having shed approximately 15% over the past month, a recent...

ImmunityBio has entered 2026 with significant momentum, propelled by a confluence of fresh clinical data, key regulatory communications, and international...

The independent public listing of Tübingen-based mRNA pioneer CureVac has been formally terminated. The company's shares have been delisted from...

Shares of AnaptysBio are trading marginally lower than the previous session's close. The company's valuation is currently tethered to a...